Site notes
This page validates as XHTML 1.0, and will look much better in a browser that supports web standards. So maybe you should...
This page validates as XHTML 1.0, and will look much better in a browser that supports web standards. So maybe you should...
Sender's message:
Sent on Friday, 2007 Nov 16.
Search breast cancer
Click on the following url to view complete results in pubmed. (Results may change over time.)
http://www.ncbi.nlm.nih.gov/entrez/cubby.fcgi?call=0_skulFTJHQSnfssD36CoLRu7AjXmaDaKmNM9MCFtLi0savhSLNqEjyuFTkQLtp&WebCubbyUser=0_htTkI963A7mqWmmaK_l1J5%401EDF213673E51460_0013SID
To unsubscribe from these e-mail updates click on the following url
http://www.ncbi.nlm.nih.gov/entrez/cubby.fcgi?call=03oJnzqQ08abzuC4CaK5CYDvC4kuqj8a6vzboFE0EcHYcQRAs&WebCubbyUser=0_htTkI963A7mqWmmaK_l1J5%401EDF213673E51460_0013SID
==================== Entrez pubmed Results ======================
Items 1 - 5 of 34
1: Ann Surg Oncol. 2007 Nov 14; [Epub ahead of print]
Terminal Duct Lobular Units are Scarce in the Nipple: Implications for
Prophylactic Nipple-Sparing Mastectomy : Terminal Duct Lobular Units in the
Nipple.
Stolier AJ, Wang J.
Tulane University Department of Surgery and Omega Hospital, 2525 Severn Ave, New
Orleans, LA, USA, astolier@tulane.edu.
BACKGROUND: The use of nipple-sparing mastectomy (NSM) for both breast cancer
treatment and risk reduction is increasing. There is no randomized data
comparing nipple-sparing mastectomy with standard mastectomy techniques. There
is evidence to suggest that ductal and lobular breast cancer arises in the
terminal duct/lobular unit (TDLU). This study was undertaken to determine
whether TDLUs exist in the nipple and if so, to what extent. METHODS: At the
time of mastectomy the nipple papilla was excised and submitted for separate
pathological examination. The presence or absence of TDLUs was noted. RESULTS:
Thirty-two nipples were studied in 22 patients. There were no TDLUs in 29
specimens. Three of 32 nipple specimens were found to contain TDLUs. The three
nipples contain one, two, and three TDLUs respectively. All TDLUs were found at
the base of the nipple, with none located near the tip. CONCLUSIONS: The
infrequent occurrence of TDLUs in the nipple papilla supports the use of NSM for
risk reduction surgery, including for those women with BRCA1/2 mutations.
PMID: 18004629 [PubMed - as supplied by publisher]
2: Exp Oncol. 2007 Sep;29(3):192-196.
Dihydropyrimidine dehydrogenase activity correlates with fluorouracil
sensitivity in breast cancer.
Yu Z, Yang Q, Sun J, Zhen J.
Department of Breast Surgery, the Second Affiliated Hospital of Shandong
University, Ji'nan, Shandong Province, People's Republic of China.
yzg@medmail.com.cn.
The fluoropyrimidine drug fluorouracil (FU) is one of the most frequently
prescribed chemotherapeutic drugs for the curative and palliative treatment of
various cancer patients. The identification of biological factors associated
with tumors either responsiveness or resistance to FU chemotherapy, including
FU, is increasingly being recognized as an important field of clinical cancer
research. AIM: to analyze the relationship between intra-tumoral
dihydropyrimidine dehydrogenase (DPD) level and FU chemosensitivity, as DPD is
the initial and rate-limiting enzyme in the catabolism of FU. MATERIALS AND
METHODS: The histoculture drug response assay (HDRA) was performed for 54
patients. DPD expression was examined in 81 tumor samples from breast cancer
patients received two cycles of FU-based primary chemotherapy before operation.
RESULTS: We found that intra-tumoral DPD enzyme activity was inversely
correlated with FU cytotoxicity. We also revealed that low DPD expression was
correlated with clinical response to FU-based primary chemotherapy. CONCLUSIONS:
Our study indicated that DPD is a promising molecular maker for identifying
tumor cells sensitivity in breast cancer patients receiving FU-based
chemotherapy.
PMID: 18004243 [PubMed - as supplied by publisher]
3: Oncology. 2007 Nov 15;72(1-2):118-124 [Epub ahead of print]
Phase I Study of Paclitaxel and Uracil plus Tegafur Combination in Patients with
Pretreated Metastatic Breast Cancer: Drug Sequencing Based on Preclinical
Modelling Studies.
Passardi A, Maltoni R, Milandri C, Cecconetto L, Massa I, Zoli W, Tesei A,
Fabbri F, Nanni O, Amadori D.
Department of Medical Oncology, Morgagni-Pierantoni Hospital, Forli, Italy.
Objective: Taxanes and fluoropyrimidines are active in metastatic breast cancer
(MBC), and their combination has proven effective in anthracycline-refractory
patients. We conducted a phase I study to determine the maximum tolerated dose
(MTD) of uracil plus tegafur (UFT) given in combination with leucovorin (LV) and
paclitaxel (Pacl) in patients with refractory MBC. Methods: Pacl was infused at
a fixed dose of 150 mg/m(2) on day 1. UFT, at doses escalated by 50 mg/m(2)
starting from 200 mg/m(2) . day, and LV, at a fixed dose of 90 mg/day, were
given orally every 8 h for 11 days (days 3-13). Cohorts of at least 3 patients
were treated at each dose level, and if 1 experienced dose-limiting toxicity
(DLT), a maximum of 3 additional patients were added at the same dose level. MTD
was reached if 2 out of the 6 patients experienced DLT. Results: Sixteen
patients were enrolled in the study. The most important toxicity observed was
hematological. Nonhematological toxicities were paresthesia and myalgia,
asthenia, nausea, and mucositis. DLT occurred in only 1 patient (grade 3 hepatic
toxicity). Conclusions: The recommended dose for a subsequent phase II trial is
Pacl 150 mg/m(2) on day 1, and UFT 300 mg/m(2) and LV 90 mg on days 3-13, every
2 weeks. Copyright (c) 2007 S. Karger AG, Basel.
PMID: 18004083 [PubMed - as supplied by publisher]
4: Oncology. 2007 Nov 14;72(1-2):75-81 [Epub ahead of print]
The Roles of Serum Leptin Concentration and Polymorphism in Leptin Receptor Gene
at Codon 109 in Breast Cancer.
Liu CL, Chang YC, Cheng SP, Chern SR, Yang TL, Lee JJ, Guo IC, Chen CP.
Department of General Surgery, Mackay Memorial Hospital, Taipei, Taiwan.
Aims: We investigated the relationship between serum leptin concentrations and
polymorphism of the leptin receptor gene and breast cancer. Methods: Serum
leptin concentrations were measured by enzyme-linked immunosorbent assay in 47
women with invasive breast cancer compared with 41 age-matched controls without
cancer. Genomic DNA was extracted from peripheral blood leukocytes. Genotyping
of the leptin receptor gene at codon 109 (LEPR-109) was performed by polymerase
chain reaction-restriction fragment length polymorphism. Results: Patients with
breast cancer had a higher mean serum leptin concentration than women in the
control group, but the difference was not statistically significant. Among those
with breast cancer, the serum leptin concentration was higher in women with
high-grade cancers (p = 0.020). The LEPR-109RR genotype was more frequent in
premenopausal patients with tumors larger than 2 cm (p = 0.039) and in
premenopausal women who were overweight (p = 0.029). Among patients with the
LEPR-109RR genotype, higher mean serum leptin concentrations were present in
those with triple-negative cancers (p = 0.048). Conclusions: Our study suggests
an association between serum leptin concentration and tumor progression.
LEPR-109 polymorphism in premenopausal women appears to be associated with
obesity and tumor progression. Copyright (c) 2007 S. Karger AG, Basel.
PMID: 18004080 [PubMed - as supplied by publisher]
5: Oncology. 2007 Nov 13;72(1-2):51-57 [Epub ahead of print]
An Open-Label, Multicenter Study of Outpatient Capecitabine Monotherapy in 631
Patients with Pretreated Advanced Breast Cancer.
Venturini M, Paridaens R, Rossner D, Vaslamatzis MM, Nortier JW, Salzberg M,
Rodrigues H, Bell R.
Medical Oncology Department, Negrar, Italy.
Background: Phase II/III trials have shown that capecitabine is an active,
well-tolerated therapy for metastatic breast cancer (MBC). We report clinical
findings from an expanded access program enabling patients ineligible for
investigative trials to receive capecitabine before its approval and
availability. Methods: Patients pretreated with at least two chemotherapy
regimens, including a taxane, for MBC received oral capecitabine until disease
progression or unacceptable toxicity. Results: Six hundred and thirty-one
patients received capecitabine (mean duration 3.8 months, range 0.1-24.7
months). The most common treatment-related grade 3/4 toxicities were diarrhea
(9%) and hand-foot syndrome (8%). Grade 3/4 alopecia was absent and grade 3/4
myelosuppression was rare. Dose was modified in 172 patients (27%). Objective
response rate in 349 evaluable patients was 35%. Median time to progression (n =
604) was 6.6 months (95% confidence interval, CI, 5.6-7.6) and median overall
survival (n = 569) was 10.0 months (95% CI, 8.5-15.3). Conclusions: Our findings
in a cohort of patients with pretreated progressive breast cancer confirm the
high efficacy and tolerability of outpatient capecitabine. Copyright (c) 2007 S.
Karger AG, Basel.
PMID: 18004077 [PubMed - as supplied by publisher]